Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation

Ferring

Status: Completed

Conditions: Prostate Cancer

Treatments: Drug: Degarelix or GnRH agonist

Study type: Observational

Funder types: Industry

Identifiers

NCT01729676

000059

Details and patient eligibility

About

French epidemiological data have shown a heterogeneous distribution of the risk of mortality from prostate cancer according to region. The main objective is to describe the distribution of prostate cancer stages when first line hormonal therapy is introduced (overall and by region).

Enrollment: 315 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with histologically demonstrated prostatic adenocarcinoma.
• Patients never previously treated with hormonal therapy for prostate cancer.
• Patients eligible for hormonal therapy after initial consultation (alone or in combination with curative treatment).
• Patients agreeing to the collection of personal health data for the purposes of the study.
• Patients with locally advanced or metastatic prostatic cancer tumours or a biological recurrence after curative treatment.

Exclusion criteria

• Patients participating in a clinical study involving prostate cancer at the time of inclusion in the investigation.
• Patients having received or currently receiving hormonal treatment for prostate cancer (surgical castration or other hormonal manipulation, including GnRH receptor antagonists, antiandrogens, oestrogens, 5 alpha reductase inhibitors).

Trial design

315 participants in 1 patient group

Group A

Description:

Degarelix or gonadotrophin releasing hormone (GnRH) agonist for treatment of prostate cancer according to physicians current practice

Treatment:

Drug: Degarelix or GnRH agonist